Compare Bristol-Myers Squibb Co (BMY) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares MSCI Hong Kong ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.88 (market cap $129.94B), while iShares MSCI Hong Kong ETF trades at $22.47. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares MSCI Hong Kong ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| BMY | EWH | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $65.89 | $24.55 |
52-Week Low | $42.60 | $20.66 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
EWH, a US-listed ETF tracking Hong Kong equities, trades at $22.45, down 1.54% in the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF announced a $0.35 dividend payable in June 2026. Recent news highlights the Hang Seng Index's rebound, driven by technology stock recoveries, contrasting with declines in other Asian markets like the Kospi and Nikkei 225.
The outlook for EWH is mixed, with potential upside from Hong Kong's market recovery and tech sector momentum, but risks include regional volatility and competitive pressures. Investors should weigh the ETF's exposure to Asian economic shifts and monitor earnings growth from constituent companies for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
